Advanced Filters
noise

Shenzhen, China Clinical Trials

A listing of Shenzhen, China clinical trials actively recruiting patients volunteers.

Found 201 clinical trials
J Junping Shi, Doctor

HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)

This study will evaluate the efficacy and safety and the best effective dose of HuHuangLianzonggan capsule in subjects with nonalcoholic steatohepatitis.

18 - 75 years of age All Phase 2
L Lung-Ji Chang, Ph.D

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of T-cell acute lymphoblastic leukemia (T-ALL): multi-antigen-targeted chimeric antigen receptor T cells (CAR-T) followed by engineered immune effector cytotoxic T cells (CTLs) and immune modified dendritic cell vaccine (DCvac). This …

6 - 65 years of age All Phase 1
L Liya Wei, MD

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma

This is a single arm, single center clinical study evaluating the safety and efficacy of CAR-T treatment for multiple myeloma.

18 - 75 years of age All Phase N/A

A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP

The primary objective of the study is to show that in Chinese adults with CABP, a course of IV/PO treatment with omadacycline has similar clinical efficacy as the with the comparator antibiotic, IV/PO moxifloxacin. The study is designed as a bridging study, to confirm the results of the pivotal global …

18 years of age All Phase 3
L Li Yu

Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma

Hepatocellular carcinoma is a highly heterogeneous disease. Treatment strategies for advanced hepatocellular carcinoma are limited. Phosphatidylinositol proteoglycan 3 (GPC3) is a heparan sulfate glycoprotein (HSPG) on the surface of the cell membrane. It is highly expressed in liver cancer tissues, but hardly expressed in normal liver tissues. It is an …

40 - 70 years of age All Phase N/A
J Jun Bo He

S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction

A randomized, double-blind, positive-drug parallel controlled, multicenter phase III trial of the efficacy and safety of S086 tablets in patients with chronic heart failure with reduced ejection fraction (HFrEF)

18 years of age All Phase 3
L Lung-Ji Chang, Ph.D

Direct Lentiviral Injection Gene Therapy for MLD

This is a Phase I/II clinical trial of gene therapy for treating Metachromatic leukodystrophy (MLD) using a safety and efficacy improved self-inactivating lentiviral vector TYF-ARSA to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct gene transfer clinical protocol.

1 - 50 years of age All Phase N/A
H Hannan Zhang, Bachelor

Variation in the Impact of Coffee on the Metabolic Rate

The purpose of this study is to explore variation in the impact of coffee on metabolic rate. The investigators plan to recruit healthy participants, half male and half female.

18 - 40 years of age All Phase N/A
Q Qiyong Zhu, MD

SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection

This is a Phase I/II gene therapy trial treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector (ivlv-X1) to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct intravenous lentiviral gene transfer protocol.

1 - 1 years of age Male Phase 1/2
L Lung-Ji Chang, Ph.D

Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD

This is a Phase I/II clinical trial of gene therapy for treating Metachromatic leukodystrophy (MLD) using a safety and efficacy improved self-inactivating lentiviral vector TYF-ARSA to transduce patient-derived hematopoietic stem cells (HSCs), with the goal of achieving therapeutic gene correction through transplantation of genetically modified HSCs. The primary objectives are …

1 - 50 years of age All Phase N/A

Simplify language using AI